1-4 of 4
Robert Hollingsworth
Close
Sort by
Journal Articles

Engineering Superaffinity Antibody Dependent Cellular Cytotoxcity Receptors into iPSC-Derived NK Cells As Next-Generation Immunotherapies for Cancer

Spencer Goodman, Kenyon Lyon, Katelin Hartwig, Suping Peng, Qin Li, David Murray, Davide Bernareggi, Caryn Gonsalves, Max Schabla, Guoxin Zhang, Terri Harder, Baohu Ji, Leah Mitchell, Dan S Kaufman, Robert Hollingsworth, Huang Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2060.
https://doi.org/10.1182/blood-2023-181261
Published: 2023
Journal Articles

A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy

Davide Bernareggi, Caryn Gonsalves, Max Schabla, Alejandra Garate-Carrilo, Mohammad El-Kalay, Dan S Kaufman, Robert Hollingsworth, Huang Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 1613–1614.
https://doi.org/10.1182/blood-2022-163871
Published: 2022
Journal Articles

Development of Next-Generation NK Cell Optimized Chimeric Antigen Receptors (CARs) for iPSC-Derived NK Cell Therapies Targeting Both Solid and Liquid Tumors

Lee Swanson, Kenyon Lyon, Wael Tadros, Mafalda Loreti, Tammy Babin, Benjamin Blair, Max Schabla, Paschalis Sideras, Dan S Kaufman, Robert Hollingsworth, Huang Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4540–4541.
https://doi.org/10.1182/blood-2022-163884
Published: 2022
Journal Articles

Preclinical Analyses Support Clinical Investigation of Combined PD-L1 Blockade and Anti-CD19 CAR T Cell Therapy for the Treatment of NHL

Ryan P Larson, PhD, Michael Ports, PhD, Heidi Jessup, Guadalupe Manriquez, MD, Carl Hay, Ross Stewart, PhD, Marlon Rebelatto, DVM, PhD, Robert Hollingsworth, PhD, Valerie Odegard, PhD
Journal: Blood
Blood (2015) 126 (23): 5430.
https://doi.org/10.1182/blood.V126.23.5430.5430
Published: 2015